Payment overview · 2025
General Payments
$1,183.22
68 reported records · 15 companies
Healthcare provider profile · identity verified
Harold H Hedges, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LITTLE ROCK, AR · NPI 1407849896
Verified facts
What the public records show
CMS Open Payments records show Harold H Hedges, M.D. received $1,183.22 in general payments during 2025 across 68 reported records.
GlaxoSmithKline, LLC. accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $251.19 | 21.2% | 18 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.25 | 21.0% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $186.86 | 15.8% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $140.99 | 11.9% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.16 | 11.8% | 10 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.92 | 4.4% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.07 | 2.9% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $19.07 | 1.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.69 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.31 | 1.5% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $16.13 | 1.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.82 | 1.3% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $14.78 | 1.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.42 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.56 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,183.22 | 68 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.20 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $175.73 | 13 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $133.87 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $133.87 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.23 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $118.89 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $118.89 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $111.77 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $99.63 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $75.46 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $75.46 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $67.97 | 4 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $67.97 | 4 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $67.97 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $65.84 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $41.36 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.35 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.07 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $14.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.42 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 158 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 68 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 190 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 132 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
34 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
99 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
132 | 26 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
190 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
133 | 29 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 824 | 189 |
| Atorvastatin Calcium | Atorvastatin Calcium | 746 | 210 |
| Amlodipine Besylate | Amlodipine Besylate | 611 | 166 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 445 | 127 |
| Omeprazole | Omeprazole | 424 | 114 |
| Lisinopril | Lisinopril | 366 | 94 |
| Metformin Hcl Er | Metformin Hcl | 359 | 93 |
| Losartan Potassium | Losartan Potassium | 356 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 92 |
| Gabapentin | Gabapentin | 280 | 73 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 67 |
| Simvastatin | Simvastatin | 265 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 73 |
| Sertraline Hcl | Sertraline Hcl | 238 | 59 |
| Trazodone Hcl | Trazodone Hcl | 220 | 67 |
| Escitalopram Oxalate | Escitalopram Oxalate | 213 | 46 |
| Estradiol | Estradiol | 199 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 44 |
| Ozempic | Semaglutide | 190 | 28 |
| Potassium Chloride | Potassium Chloride | 190 | 51 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 189 | 46 |
| Allopurinol | Allopurinol | 183 | 52 |
| Tramadol Hcl | Tramadol Hcl | 174 | 34 |
| Clonazepam | Clonazepam | 169 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 37 |
| Metformin Hcl | Metformin Hcl | 162 | 41 |
| Famotidine | Famotidine | 161 | 40 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 48 |
| Furosemide | Furosemide | 158 | 47 |
| Jardiance | Empagliflozin | 158 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 158 | 38 |
| Alprazolam | Alprazolam | 153 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 51 |
| Meloxicam | Meloxicam | 144 | 42 |
| Pioglitazone Hcl | Pioglitazone Hcl | 137 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 34 |
| Eliquis | Apixaban | 133 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 132 | 26 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 129 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 123 | 26 |
| Lorazepam | Lorazepam | 120 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 111 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 43 |
| Carvedilol | Carvedilol | 107 | 35 |
| Montelukast Sodium | Montelukast Sodium | 107 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 104 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 101 | 24 |
| Synthroid | Levothyroxine Sodium | 99 | 18 |
| Prednisone | Prednisone | 96 | 78 |
| Bupropion Xl | Bupropion Hcl | 94 | 26 |
| Glipizide Er | Glipizide | 87 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 87 | 25 |
| Ezetimibe | Ezetimibe | 86 | 22 |
| Raloxifene Hcl | Raloxifene Hcl | 86 | 21 |
| Spironolactone | Spironolactone | 86 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 84 | 18 |
| Alendronate Sodium | Alendronate Sodium | 80 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 62 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 16 |
| Diazepam | Diazepam | 76 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 24 |
| Mounjaro | Tirzepatide | 68 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 65 | 24 |
| Ondansetron Odt | Ondansetron | 65 | 26 |
| Fluconazole | Fluconazole | 63 | 31 |
| Irbesartan | Irbesartan | 63 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 60 | 55 |
| Amitriptyline Hcl | Amitriptyline Hcl | 58 | 15 |
| Farxiga | Dapagliflozin Propanediol | 57 | suppressed |
| Baclofen | Baclofen | 54 | 14 |
| Myrbetriq | Mirabegron | 54 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 48 |
| Donepezil Hcl | Donepezil Hcl | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 52 | 27 |
| Valsartan | Valsartan | 52 | 12 |
| Buspirone Hcl | Buspirone Hcl | 50 | 15 |
| Finasteride | Finasteride | 49 | 12 |
| Atenolol | Atenolol | 48 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 46 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 44 | 30 |
| Dicyclomine Hcl | Dicyclomine Hcl | 43 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 37 |
| Azithromycin | Azithromycin | 41 | 37 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Glimepiride | Glimepiride | 37 | 12 |
| Naproxen | Naproxen | 37 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Pregabalin | Pregabalin | 35 | 11 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 12 |
| Linzess | Linaclotide | 34 | 13 |
| Verapamil Er | Verapamil Hcl | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Dutasteride | Dutasteride | 33 | suppressed |
| Acyclovir | Acyclovir | 32 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Lovastatin | Lovastatin | 32 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Clotrimazole | Clotrimazole | 30 | 14 |
| Rizatriptan | Rizatriptan Benzoate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 27 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 12 |
| Topiramate | Topiramate | 26 | suppressed |
| Cephalexin | Cephalexin | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Premarin | Estrogens, Conjugated | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 22 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Temazepam | Temazepam | 22 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 21 | suppressed |
| Estradiol-Norethindrone Acetat | Estradiol/Norethindrone Acet | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Metronidazole | Metronidazole | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 16 |
| Colchicine | Colchicine | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 16 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 16 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Ursodiol | Ursodiol | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Forteo | Teriparatide | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,183.22 · 68 records | GlaxoSmithKline, LLC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, FARXIGA, GARDASIL 9, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, SHINGRIX, SPRAVATO, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, XYOSTED, ZAVZPRET, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error